Literature DB >> 17442921

Clinical transplantation tolerance: many rivers to cross.

Alan D Salama1, Karl L Womer, Mohamed H Sayegh.   

Abstract

Modern immunosuppressive regimens for organ transplantation have resulted in excellent short-term results but less dramatic improvements in long-term outcomes. Moreover, they are associated with significant deleterious effects. One solution that should avoid the adverse drug effects and result in improved graft and patient longevity as well as positively impacting on the organ shortage is the establishment of transplantation tolerance. Ever since the original description of transplantation tolerance in rodent allografts, there have been significant efforts made to translate tolerance-promoting strategies to the clinical arena. However, >50 years later, we are still faced with significant barriers that are preventing such a goal from being widely attained. Nonetheless, pilot clinical tolerance protocols are underway in selected transplant recipients. In this review, we discuss the scientific and nonscientific issues that must be overcome for successful transplantation tolerance to become a clinical reality.

Entities:  

Mesh:

Year:  2007        PMID: 17442921     DOI: 10.4049/jimmunol.178.9.5419

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Dynamic quantification of host Schwann cell migration into peripheral nerve allografts.

Authors:  Elizabeth L Whitlock; Terence M Myckatyn; Alice Y Tong; Andrew Yee; Ying Yan; Christina K Magill; Philip J Johnson; Susan E Mackinnon
Journal:  Exp Neurol       Date:  2010-07-12       Impact factor: 5.330

2.  Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects.

Authors:  V A L Huurman; C R van der Torren; P Gillard; R Hilbrands; E P M W van der Meer-Prins; G Duinkerken; F K Gorus; F H J Claas; B Keymeulen; D L Roelen; D G Pipeleers; B O Roep
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 3.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

4.  Transplantation tolerance; myth or reality?

Authors:  Aruna Vanikar
Journal:  J Nephropathol       Date:  2014-01-01

5.  Functionalization of Alginate with Extracellular Matrix Peptides Enhances Viability and Function of Encapsulated Porcine Islets.

Authors:  Juan D Medina; Michael Alexander; Michael D Hunckler; Marc A Fernández-Yagüe; María M Coronel; Alexandra M Smink; Jonathan R Lakey; Paul de Vos; Andrés J García
Journal:  Adv Healthc Mater       Date:  2020-04-07       Impact factor: 9.933

6.  CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.

Authors:  Carol H Miao; Benjamin R Harmeling; Steven F Ziegler; Benjamin C Yen; Troy Torgerson; Liping Chen; Roger J Yau; Baowei Peng; Arthur R Thompson; Hans D Ochs; David J Rawlings
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

Review 7.  Immune tolerance and transplantation.

Authors:  Onder Alpdogan; Marcel R M van den Brink
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

Review 8.  Recent developments in kidney transplantation--a critical assessment.

Authors:  K L Womer; B Kaplan
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

9.  Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes.

Authors:  Olivier Joffre; Thibault Santolaria; Denis Calise; Talal Al Saati; Denis Hudrisier; Paola Romagnoli; Joost P M van Meerwijk
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

10.  Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein.

Authors:  Esma S Yolcu; Xiao Gu; Chantale Lacelle; Hong Zhao; Laura Bandura-Morgan; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.